Evidence Archives

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
Gallery
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

Evidence, MammaPrint, NBRST, Neoadjuvant, Other, Racial Disparities

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Read More

kevin2024-03-25T08:51:00-04:00June 5th, 2019|Evidence, MammaPrint, NBRST, Neoadjuvant, Other, Racial Disparities|

2019 ASCO FLEX Poster
Gallery
2019 ASCO FLEX Poster

Evidence, FLEX TIPS, MammaPrint, Other

2019 ASCO FLEX Poster

AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Read More

kevin2024-03-25T08:51:45-04:00June 4th, 2019|Evidence, FLEX TIPS, MammaPrint, Other|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Gallery
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

kevin2024-03-25T11:24:02-04:00June 1st, 2019|Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe|

NBRST: ER-positive basal-type breast cancers, respond like TNBC

NPJ Breast Cancer, April 2019 Author: Groenendijk et al.

Read More

Karen Guzdzial2024-04-16T11:49:27-04:00April 21st, 2019|Evidence, NBRST, Neoadjuvant|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
Gallery
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

Evidence, NBRST, Neoadjuvant

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

kevin2024-03-25T08:54:30-04:00April 18th, 2019|Evidence, NBRST, Neoadjuvant|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
Gallery
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint, Evidence, Other, Validation

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

kevin2024-03-25T08:56:28-04:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

2018 SABCS FLEX Trials in Progress Poster
Gallery
2018 SABCS FLEX Trials in Progress Poster

Evidence, FLEX TIPS, MammaPrint, Other

2018 SABCS FLEX Trials in Progress Poster

AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Read More

kevin2024-09-26T13:55:16-04:00December 5th, 2018|Evidence, FLEX TIPS, MammaPrint, Other|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
Gallery
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

kevin2024-03-27T10:20:24-04:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Gallery
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Adjuvant, Evidence, MammaPrint, PROMIS

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More

kevin2024-03-25T08:57:37-04:00January 11th, 2018|Adjuvant, Evidence, MammaPrint, PROMIS|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
Gallery
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Endocrine, Evidence, MammaPrint, STO-3

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More

kevin2024-06-28T12:13:13-04:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a	never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.

Cookie	Duration	Description
c	6 months 2 days	Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.
uuid	1 year 1 month	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	YouTube sets this cookie to store the user's cookie consent state for the current domain.
YSC	session	Youtube sets this cookie to track the views of embedded videos on Youtube pages.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Cookie	Duration	Description
yt-remote-cast-installed	session	The yt-remote-cast-installed cookie is used to store the user's video player preferences using embedded YouTube video.
yt-remote-connected-devices	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-device-id	never	YouTube sets this cookie to store the user's video preferences using embedded YouTube videos.
yt-remote-fast-check-period	session	The yt-remote-fast-check-period cookie is used by YouTube to store the user's video player preferences for embedded YouTube videos.
yt-remote-session-app	session	The yt-remote-session-app cookie is used by YouTube to store user preferences and information about the interface of the embedded YouTube video player.
yt-remote-session-name	session	The yt-remote-session-name cookie is used by YouTube to store the user's video player preferences using embedded YouTube video.
ytidb::LAST_RESULT_ENTRY_KEY	never	The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

2019 ASCO FLEX Poster

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

2018 SABCS FLEX Trials in Progress Poster

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

RON KALFUS

STEPHANIE BYWATER